Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
Wednesday, April 25, 2018 BiopharmaWatch Research 1 min read
Key Takeaway: Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers
Full Press Release Details
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody.